Do Kyun Kang, Min Kyun Kang, Woon Heo, Youn-Ho Hwang
{"title":"Single center experience of uniportal VATS anatomical lung resections: Mid-term oncological outcomes.","authors":"Do Kyun Kang, Min Kyun Kang, Woon Heo, Youn-Ho Hwang","doi":"10.1111/1759-7714.13774","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Uniportal video-assisted thoracoscopic surgery (VATS) anatomical lung resection has become widely accepted for its favorable outcomes with regard to pain. However, oncological outcomes, especially mid- or long-term outcomes, are still lacking. The objective of this study was to present our eight-year experience of uniportal VATS anatomical lung resection, including mid-term oncological outcomes.</p><p><strong>Methods: </strong>All consecutive patients undergoing uniportal VATS anatomical lung resection between June 2012 and February 2020 were reviewed retrospectively.</p><p><strong>Results: </strong>We analyzed data of 170 patients (100 male and 70 female), with a median age of 67 years. The median follow-up time was 21 months (range 11-41). The DFS of the entire cohort was 66.3 months. Stage-correlated DFS was 73.1 months for stage I, 42.6 months for stage II, 30.6 months for stage III and 12.5 months for stage IV. The OS of the entire court was 67 months. Stage-correlated OS was 75.6 months for stage I, 50.2 months for stage II, 31.7 months for stage III and 12.5 months for stage IV.</p><p><strong>Conclusions: </strong>Uniportal VATS anatomical lung resection for lung cancer can be performed with satisfactory mid-term histology- and stage-related outcomes, which is consistent with prior results of traditional VATS or thoracotomy.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"12 7","pages":"1006-1013"},"PeriodicalIF":2.3000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/1759-7714.13774","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.13774","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Uniportal video-assisted thoracoscopic surgery (VATS) anatomical lung resection has become widely accepted for its favorable outcomes with regard to pain. However, oncological outcomes, especially mid- or long-term outcomes, are still lacking. The objective of this study was to present our eight-year experience of uniportal VATS anatomical lung resection, including mid-term oncological outcomes.
Methods: All consecutive patients undergoing uniportal VATS anatomical lung resection between June 2012 and February 2020 were reviewed retrospectively.
Results: We analyzed data of 170 patients (100 male and 70 female), with a median age of 67 years. The median follow-up time was 21 months (range 11-41). The DFS of the entire cohort was 66.3 months. Stage-correlated DFS was 73.1 months for stage I, 42.6 months for stage II, 30.6 months for stage III and 12.5 months for stage IV. The OS of the entire court was 67 months. Stage-correlated OS was 75.6 months for stage I, 50.2 months for stage II, 31.7 months for stage III and 12.5 months for stage IV.
Conclusions: Uniportal VATS anatomical lung resection for lung cancer can be performed with satisfactory mid-term histology- and stage-related outcomes, which is consistent with prior results of traditional VATS or thoracotomy.
期刊介绍:
Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society.
The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.